10% Easter Discount only until Tuesday 25th
There is an Easter Egg hidden somewhere on our home page. Find it, click on it and register for 10% discount on your first order until end of May.
New summaric presentation of epitope fingerprinting technology available
EPITOPIC participates in a Danish/German consortium to develop a novel type of vaccines against bacterial infections. “This
is the first time we are broadly applying our recently optimized software for the mapping of antibodies in vaccine sera”, says
Marcus Puder, who has developed the new tools at epitopic. “We could support academia in the discovery of corona virus
epitopes, but this will now enable our partners to discover and understand the epitopes relevant for an efficient and protective
immune response against urinary tract infections!”
Download press release (English, German)
For COVID-19 epitope mapping applying the EPITOPIC software Fraunhofer receives a grant by the Federal Ministry of Education
and Research (BMBF). This is one of those grants given specially to research focussed on aspects of the pandemic.
New hardware allows to carry out the in silico analyses at a very much increased speed. The new setup enables one epitope
per 2-4 hours instead of 2 days.
EPITOPIC moves to BIO CITY Leipzig.
Due to an unexpected shut down of the Fraunhofer Institute, caused by the corona pandemic, the operations of EPITOPIC came
down to a minimum.
With support by EPITOPIC a Fraunhofer research group generates epitope fingerprints of Dupilumab and anti-drug antibodies
of an allergy patient from Leipzig’s University Hospital in less than three weeks. (see publications)
2019 had an unexpected record number of projects: CEO Michael Szardenings can announce that the overall capacity utilization
in 2019 was close to 90%. EPITOPIC reacts by expanding resources in particular the IT sector to serve all customers in the
shortest possible time.
US-Patent on in-licensed Phage Library granted: The library design that is the one of the three essential keys to epitope
fingerprinting with statistical peptide phage display has now also received protection in the US.